Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYH33 (Risovalisib) + Endocrine Therapy ± Palbociclib in Advanced Breast Cancer
NCT04856371Phase 1Unknown
- Sponsor
- Haihe
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of risovalisib mesylate in breast cancer (3 arms), sponsored by Haihe. Primary endpoint: Dose Limiting Toxicities at 28 days. Status: unknown.
02
Drugs
risovalisib mesylate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04856371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856371.